Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a heart condition caused by abnormal protein buildup, known as ATTR cardiomyopathy (ATTR-CM)
- People who are starting treatment with a medication called vutrisiran, or another approved medication for ATTR-CM
Who may not be able to join:
- People who are already taking part in another clinical trial that involves a medical treatment or intervention
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Alnylam Pharmaceuticals
Phone: 1-877-ALNYLAM
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
New York Heart Association (NYHA) Class; Outpatient Diuretic Intensification; Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Total Score; Kansas City Cardiomyopathy Questionnaire (KCCQ); Patient Global Impressions - Change (PGI-C); Patient Global Impressions - Severity (PGI-S);; Treatment Satisfaction Questionnaire for Medication version 9 (TSQM-9)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.